These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 1146004)

  • 1. The effects of varying dialysis regimens on lymphocyte stimulation.
    Hurst KS; Saldanha LF; Steinberg SM; Galen MA; Lowrie EG; Gagneux SA; Lazarus JM; Strom TB; Carpenter CB; Merrill JP
    Trans Am Soc Artif Intern Organs; 1975; 21():329-34. PubMed ID: 1146004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro reactivity of lymphocytes obtained from uraemic patients maintained by heamodialysis.
    Sengar DP; Rashid A; Harris JE
    Clin Exp Immunol; 1975 Aug; 21(2):298-305. PubMed ID: 126831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MLC-blocking factors in uremic sera.
    Fehrman I; Ringdén O; Bergström J
    Clin Nephrol; 1980 Oct; 14(4):183-9. PubMed ID: 7000408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Tuberculosis in compromised hosts].
    Kekkaku; 2003 Nov; 78(11):717-22. PubMed ID: 14672050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone pain in dialysis patients is not associated with bone mineral density but with serum concentration of small uremic toxins.
    Grzegorzewska AE; Młot-Michalska M
    Adv Med Sci; 2007; 52():228-31. PubMed ID: 18217423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intradialytic changes of serum magnesium and their relation to hypotensive episodes in hemodialysis patients on different dialysates.
    Elsharkawy MM; Youssef AM; Zayoon MY
    Hemodial Int; 2006 Oct; 10 Suppl 2():S16-23. PubMed ID: 17022745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of uremic middle molecules on in vitro stimulated lymphocytes and interleukin-2 production.
    Severini G; Diana L; Di Giovannandrea R; Sagliaschi G
    ASAIO J; 1996; 42(1):64-7. PubMed ID: 8808461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The beneficial effect of ketoacids on serum phosphate and parathyroid hormone in patients with chronic uremia.
    Schaefer K; von Herrath D; Asmus G; Umlauf E
    Clin Nephrol; 1988 Aug; 30(2):93-6. PubMed ID: 3180519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of serum and plasma from hemodialysis patients on the lymphoproliferative response.
    Miyakoshi H; Aoki T; Hirasawa Y
    Clin Nephrol; 1979 Dec; 12(6):263-8. PubMed ID: 527279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of hemodialysis on the distribution of phosphates in blood.
    Sarkozi L; Szabo A
    Clin Physiol Biochem; 1989; 7(3-4):184-8. PubMed ID: 2805568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defective cellular immunity in renal failure: depression of reactivity of lymphocytes to phytohemagglutinin by renal failure serum.
    Newberry WM; Sanford JP
    J Clin Invest; 1971 Jun; 50(6):1262-71. PubMed ID: 5578233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of sevelamer hydrochloride on serum concentration of whole (1-84) and N-terminally truncated (7-84) parathyroid hormone fragments in hemodialysis uremic patients.
    Chudek J; Piecha G; Kokot F; Wiecek A
    J Nephrol; 2003; 16(5):710-5. PubMed ID: 14733418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum ionized calcium, parathyroid hormone and phosphate in uremic patients during and between hemodialysis.
    Rudnicki M; Frølich A; Haaber A; Tvedegaard E; Thode J
    Clin Nephrol; 1993 Oct; 40(4):225-9. PubMed ID: 8261680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Middle molecule accumulation in uremia: an "extra uremic factor".
    Oulès R; Emond C; Claret G; Branger B; Mion H; Mion C
    Artif Organs; 1981; 4 Suppl():177-83. PubMed ID: 7295089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical experience with the REDY dialysis system.
    Jans H; Kaern J; Nielsen B; Pleidrup E
    Scand J Urol Nephrol; 1976; (30 Suppl):32-8. PubMed ID: 935816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunosuppressive factors in uraemic sera are composed of both dialysable and non-dialysable components.
    Kamata K; Okubo M; Sada M
    Clin Exp Immunol; 1983 Oct; 54(1):277-81. PubMed ID: 6616971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low Ca2+ dialysate. Effects on bone metabolism in the course of paired filtration dialysis.
    Carozzi S; Nasini MG; Pietrucci A; Costa M; Mantero R
    ASAIO J; 1994; 40(3):M683-5. PubMed ID: 8555601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of uremic serum and 3'-5' cyclic AMP on blastogenesis of normal lymphocytes.
    Modai D; Weissgarten J; Cohen N; Averbukh Z; Golik A; Peller S; Tieder M; Shaked U; Kaufman S
    Thymus; 1986; 8(5):307-11. PubMed ID: 3026066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunologic disturbances and levels of parathyroid hormone in uremic patients in replacement dialysis therapy.
    Angelini D; Carlini A; Mazzotta L; Mei E; Grassi R; Giusti R; Neri M; Fiorini I; Antonelli A
    Clin Nephrol; 1994 Oct; 42(4):246-50. PubMed ID: 7834917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.